FBInvestor
Stocks / Celldex Therapeutics Inc New
Institutional Ownership

Celldex Therapeutics Inc New

CUSIP 15117B202COM NEWCLDXQ1 2026

13D / 13G Filings
63
Schedule 13D/13G on record
Beneficial Filers
25
Distinct reporting persons
Largest Stake
15.0%
Max % of class reported
Institutional Holders
221
13F filers (latest quarter)

Beneficial Owners — Schedule 13D / 13G

63 filings · latest Mar 10, 2026

Export CSV — Pro
#FiledReporting PersonForm% of ClassSharesFiling
1Mar 10, 2026Point72 Asset Management, L.P.13G/A2.6%1.76MSEC
2Feb 10, 2026Wellington Management Group LLP13G/A12.2%8.08MSEC
3Feb 9, 2026State Street Corporation13G5.1%3.40MSEC
4Nov 14, 2025Commodore Capital LP13G/A11.0%3.03MSEC
5Nov 14, 2025Bellevue Group AG13G5.4%3.62MSEC
6Nov 14, 2025T. Rowe Price Associates, Inc.13G/A3.6%2.38MSEC
7Nov 7, 2025Wellington Management Group LLP13G/A11.1%7.39MSEC
8Aug 14, 2025Eventide Asset Management, LLC13G/A2.0%SEC
9Aug 12, 2025Wellington Management Group LLP13G/A7.9%5.23MSEC
10Jul 10, 2025Point72 Asset Management, L.P.13G6.7%4.46MSEC

53 more beneficial-ownership filings on Premium

See the full Schedule 13D/13G history for Celldex Therapeutics Inc New.

Unlock full history

Top Institutional Holders (13F)

Largest reported positions · latest quarter

View all →
#FundSharesValue
1Wellington Management Group LLP8.56M$271.54M
2Kynam Capital Management, LP5.84M$185.26M
3Blackrock, Inc.5.37M$170.33M
4Fmr LLC3.75M$118.92M
5Point72 Asset Management, L.P.3.23M$102.45M
6State Street Corp2.80M$88.95M
7Commodore Capital LP2.70M$85.54M
8Eversept Partners, LP1.79M$56.72M
9Geode Capital Management, LLC1.69M$53.56M
10Braidwell LP1.36M$43.01M